Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline

In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Kyung-Jin, Kwon, Sang-Hoon, Kim, Kidong, Kim, Sunghoon, Kim, Hyun Jung, Seong, Seok Ju, Song, Yong Jung, Lee, Keun Ho, Lee, Shin-Wha, Lee, Jeong-Won, Chang, Suk-Joon, Ju, Woong, Kim, Young-Tak, Lee, Jae-Kwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2019
Materias:
Practice Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393630/
https://www.ncbi.nlm.nih.gov/pubmed/30740959
http://dx.doi.org/10.3802/jgo.2019.30.e31
Descripción
Sumario:In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.

Ejemplares similares